A recent study has shed new light on the potential benefits of cannabis compounds in improving liver health. The research, published in the British Journal of Pharmacology, found that CBD and CBG, two non-psychoactive compounds found in cannabis, may help alleviate symptoms of metabolic dysfunction-associated steatotic liver disease (MASLD). This chronic condition is becoming increasingly common worldwide.
The study, which used obese mice as test subjects, revealed that CBD and CBG were able to reduce liver fat, improve blood sugar control, and normalize lipid levels. These findings are significant because they target the root cause of MASLD, which is metabolic dysfunction.
The study’s results suggest that CBD and CBG may be a potential breakthrough in the treatment of fatty liver disease. However, experts are urging caution before drawing conclusions about the real-world applications of these compounds. Further research is needed to fully understand the benefits and limitations of using CBD and CBG to improve liver health.
